Press Releases Alzamend Neuro, Inc.

Equities

ALZN

US02262M4078

Market Closed - Nasdaq Other stock markets 21:30:00 10/05/2024 BST			5-day change	1st Jan Change
0.5432 ^USD	-7.93%		-26.10%	-38.97%

05-09	Alzamend Neuro, Inc. announced that it expects to receive $25 million in funding	CI
03-25	Alzamend Neuro, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2024	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Alzamend Neuro Announces Agreement for Registered Direct Offering and Concurrent Private Placement for an Aggregate of up to $25 Million	05-09	BU
Alzamend Neuro Announces Termination of At-the-Market Equity Offering Program	05-07	BU
Alzamend Neuro Receives FDA Study May Proceed Notification for a Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Post-Traumatic Stress Disorder Patients	12-12	AQ
Alzamend Neuro Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Post-Traumatic Stress Disorder Patients	12-11	BU
Alzamend Neuro Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next‑Generation Lithium Therapeutic Drug Candidate, in Major Depressive Disorder Patients	11-20	BU
Alzamend Neuro Regains Compliance with Nasdaq's Minimum Bid Price Requirement	11-17	AQ
Alzamend Neuro Regains Compliance with Nasdaq’s Minimum Bid Price Requirement	11-16	BU
Alzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Post-Traumatic Stress Disorder Patients of Next‑Generation Lithium Therapeutic Drug Candidate AL001	11-13	BU
Alzamend Neuro Announces Reverse Stock Split	30/10/23	BU
Alzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Major Depressive Disorder Patients of its Next-Generation Lithium Therapeutic Drug Candidate AL001	24/10/23	AQ
Alzamend Neuro Submits IND Application for a Phase IIA Clinical Trial in Major Depressive Disorder Patients of its Next‑Generation Lithium Therapeutic Drug Candidate AL001	23/10/23	BU
Alzamend Neuro Receives FDA 'Study May Proceed' Notification for a Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder Patients	03/10/23	AQ
Alzamend Neuro Receives FDA “Study May Proceed” Notification for a Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder Patients	02/10/23	BU
Alzamend Neuro Granted Extension by Nasdaq Panel to Regain Compliance with the Minimum Bid Price Continued Listing Requirement	25/09/23	AQ
Alzamend Neuro Granted Extension by Nasdaq Panel to Regain Compliance with the Minimum Bid Price Continued Listing Requirement	22/09/23	BU
Alzamend Neuro Submits IND Application for Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder Patients	30/08/23	BU
Alzamend Neuro : Failure to Satisfy Listing Rule - Form 8-K	07/08/23	PU
ALZAMEND NEURO, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)	22/06/23	AQ
Alzamend Neuro Announces Positive Phase IIA Clinical Trial Results for AL001	22/06/23	BU
Alzamend Neuro CEO Stephan Jackman to Participate on the “Mental Health, More Critical Than Ever” Panel at the Maxim Group’s Virtual Healthcare Conference	13/06/23	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Alzamend Neuro, Inc.

Equities

ALZN

US02262M4078

Press Releases

Filters